21Shares has filed for a new exchange-traded fund (ETF) focused on Injective (INJ), as reported by Coin Bureau. This filing, made in October 2025, marks a pivotal step in linking decentralized finance (DeFi) with traditional financial systems, making Injective one of the few digital assets with multiple ETF products in development.
Injective is a high-performance blockchain built for DeFi, capable of handling over 25,000 transactions per second and utilizing a delegated proof-of-stake mechanism for security. Its native token, INJ, addresses common blockchain challenges like slow transaction finality and fragmented liquidity by combining exchange features with fast finality powered by Comet BFT.
The proposed ETF would hold INJ tokens in cold storage, similar to spot ETFs for Bitcoin and Ethereum, ensuring security while allowing investors to track market prices without managing private keys. This move highlights growing institutional interest, as traditional finance firms seek regulated ways to offer crypto exposure to clients.
Currently under regulatory review, approval could encourage more ETFs on DeFi tokens, fostering greater institutional participation and mainstream adoption of decentralized technologies.
TEA
BTC
ETH
BNB
KSGT
ENA
MEME
SPEC
MAVIA
ICNT